Dev

NEW STRATEGY FOR THE TREATMENT OF EA: VALIDATION OF EPIGENETIC DIANAS, FROM IN-VITRO TO A MURINATE MODEL OF DISEASE. DESIGN AND DEVELOPMENT OF NEW PHARMACOLOGICAL TOOLS Investments < €500k Spain 2016    

THERAPEUTIC STRATEGIES AGAINST THE TOXICITY PRODUCED BY PEPTIDES AND RNA CODED BY THE ALTERATION OF HTT MUTANT IN HUNTINGTON DISEASE Investments < €500k Spain 2016    

ALTERATIONS OF THE METABOLIC PROFILE INDUCED BY LRRK2 PATHOGENIC MUTATIONS AS PARKINSON DISEASE BIOMARKERS Investments < €500k Spain 2016    

SEARCH FOR NEW THERAPEUTIC DIANES IN PARKINSON’S DISEASE. ANALYSIS OF CELL RECYCLING SYSTEMS AND MITOCHONDRIAL STATUS IN CELLS FROM PATIENTS. Investments < €500k Spain 2016    

PROCESSING BY SECRETS OF THE COLINERGIC FORM OF ACETYLCOLINESTERASE, ITS TRANSCRIPTIONAL ACTIVITY AND IMPLICATION IN ALZHEIMER’S DISEASE. Investments < €500k Spain 2016    

STUDY OF THE PATTERN OF DNA MOLTING IN THE HYPOCAMPUS OF PATIENTS WITH ALZHEIMER’S DISEASE Investments < €500k Spain 2016    

ALZHEIMER DISEASE Biomarkers AS PROGNOSTIC FACTORS IN NORMAL IDIOPATHIC PRESSURE HYDROCEPHALISM Investments < €500k Spain 2016    

BIOCHEMICAL AND ELECTROPHYSIOLOGICAL CHANGES IN NST / SNR ECP IN PATIENTS WITH PARKINSON DISEASE AND ALTERATION OF THE MARCH Investments < €500k Spain 2016    

EVALUATION OF THE DIAGNOSTIC CAPACITY OF OPTICAL COHERENCE TOMOGRAPHY OF SPECTRAL DOMINION TO DIFFERENTIATE BETWEEN PARKINSON’S DISEASE AND ATIPIC PARKINSONISMS Investments < €500k Spain 2016    

MULIDIDIAN CHIRAL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES: NICOTYL RECEPTOR LIGANDS, NRF2 AND ANTI-INFLAMMATORY INDUCTORS Investments < €500k Spain 2016